Novo Nordisk/X
Aug 2, 2025, 03:50
FDA Approves Novo Nordisk Prophylactic Treatment for Hemophilia A and B
Novo Nordisk US has shared a proud post on X:
“PRESS: Novo Nordisk receives US FDA approval for a new indication for a prophylactic treatment to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B without inhibitors. ”
To learn more, follow the link.
Stay informed with Hemostasis Today.
-
Nov 14, 2025, 11:58Marilena Vrana: Can Public-only Blood Collection Systems Meet the Growing Patient Need for PDMs?
-
Nov 14, 2025, 11:48Cedric Hermans Shares the 1st Illustrated Review Dedicated to Hemophilia B
-
Nov 14, 2025, 10:28Valance Washington: Proud to Share Our Lab’s Latest Publication in Platelets Journal
-
Nov 14, 2025, 10:18Sripal Bangalore and Ajay Kirtane on TUXEDO-2 Comparison Focusing on Diabetic Patients
-
Nov 14, 2025, 10:11Ashley Lawrenson on Her Coagulation Journey Using Automation With the HemoCell and HemoHub
-
Nov 14, 2025, 10:05Kingsley Wheaton: A Year Ago, Omni Was an Idea – Today, It’s a Movement!
-
Nov 14, 2025, 09:58Rucha Patil Takes The National DHR-ICMR Gold Award for Best Technology
-
Nov 14, 2025, 09:48Caitlin Raymond on ”The Plasma Chasers”
-
Nov 14, 2025, 09:42Erin VanDyke on Why They Do In-person Site Visits for NBCA Centers of Excellence Designation!